Sorted By:

Relevance


Who Benefits from the 340B Drug Discount Program?

PhRMA  |  Blog Post

To learn more about 340B, follow our 340B Spotlight series or sign-up for personalized email updates here
http://catalyst.phrma.org/who-benefits-from-the-340b-drug-discount-program

340B Spotlight: Despite access to discounts, many 340B hospitals fail to comply with ACA charity care requirements

PhRMA  |  Blog Post

For more on 340B, check out our latest 340B Spotlight posts.
http://catalyst.phrma.org/340b-spotlight-despite-access-to-discounts-many-340b-hospitals-fail-to-comply-with-aca-charity-care-requirements

340B Spotlight: Program continues to grow with no end in sight

PhRMA  |  Blog Post

Presented at: 340B Coalition Winter Conference.
http://catalyst.phrma.org/340b-spotlight-program-continues-to-grow-with-no-end-in-sight

Follow the Dollar: Flow of Payment for a $400 Insulin

PhRMA  |  Graphic

Scott takes insulin for his type 2 diabetes and has a health plan with a high deductible. ...
https://www.phrma.org/graphic/follow-the-dollar-flow-of-payment-for-a-400-insulin

Most 340B Hospitals Provide Little to Below Average Levels of Charity Care

Chartpack  |  From Our Network

Sixty-nine percent of 340B hospitals report charity care levels below the national average of 3.3%; 24% report levels below 1% of total costs.
http://chartpack.phrma.org/programs-chartpack/medicines-in-340b/most-340b-hospitals-provide-little-to-below-average-levels-of-charity-care

Administration’s Special 301 Report highlights deteriorating global environment for biopharmaceutical innovation

PhRMA  |  Blog Post

PhRMA is encouraged by the Administration’s emphasis on the importance of enforcing obligations in existing trade agreements and bilateral discussions.
http://catalyst.phrma.org/administrations-special-301-report-highlights-deteriorating-global-environment-for-biopharmaceutical-innovation

340B Spotlight: New study raises questions about whether non-profit hospitals are meeting charity care requirements in Affordable Care Act

PhRMA  |  Blog Post

The administration recently released a new proposed guidance on the 340B program, but it did not introduce any new requirements to ensure that patients benefit from the 340B discount at the non-profit hospitals that participate in the program.
http://catalyst.phrma.org/340b-spotlight-new-study-raises-questions-about-whether-non-profit-hospitals-are-meeting-charity-care-requirements-in-affordable-care-act

340B Spotlight: New Charity Care Data Shows Most Hospitals with Contract Pharmacies Provide Little Charity Care

PhRMA  |  Blog Post

Get updates on 340B and other issues here.
http://catalyst.phrma.org/340b-spotlight-new-charity-care-data-shows-most-hospitals-with-contract-pharmacies-provide-little-charity-care

PhRMA Statement on 2014 Special 301 Report

PhRMA  |  Press Release

The Special 301 process garners the high-level attention from our trading partners necessary to redress intellectual property violations and market access concerns within individual markets and to send signals to other U.S. trading partners that protecting American intellectual property is important not only to the U.S. economy but also to patients across the globe.
https://www.phrma.org/press-release/phrma-statement-on-2014-special-301-report

Uninsured Rate Is Dropping, Yet Participation in 340B Retail Pharmacy Program Is Growing

Chartpack  |  From Our Network

The number of contract pharmacy arrangements has increased dramatically as the percentage of individuals without drug coverage has fallen. ...
http://chartpack.phrma.org/programs-chartpack/medicines-in-340b/uninsured-rate-is-dropping-yet-participation-in-340b-retail-pharmacy-program-is-growing

Disproportionate Share Hospitals Are Driving Current Volume and Future Program Growth

Chartpack  |  From Our Network

Disproportionate Share Hospitals drive 81% of 340B sales volume but only make up 9% of 340B entities.
http://chartpack.phrma.org/programs-chartpack/medicines-in-340b/disproportionate-share-hospitals-are-driving-current-volume-and-future-program-growth

PhRMA Statement on Special 301 Report

PhRMA  |  Press Release

“The Special 301 process continues to be effective in gaining high-level attention from our trading partners -- attention that is needed to redress intellectual property violations and market access concerns.
https://www.phrma.org/press-release/phrma-statement-on-special-301-report

PhRMA Comments on the 2010 Special 301 Report

PhRMA  |  Press Release

“The Special 301 process continues to be effective in gaining high-level attention from our trading partners, attention that is needed to redress intellectual property violations and market access concerns.
https://www.phrma.org/press-release/phrma-comments-on-the-2010-special-301-report

Aspen Spotlight Health 360° VIDEO PREMIERE:
New Virtual Reality Video Takes You Inside The Lab with Researchers to Showcase Amazing Advancements in Medicine

PhRMA  |  Press Release

WHAT:  America’s Biopharmaceutical Companies’ GoBoldly Exhibit & 360° Video Experience WHEN: Thursday June 22 from 8:30 am – 5:00 pm Friday June 23 from 8:30 am – 5:00 pm Saturday June 24 from 8:30 am – 5:00 pm WHERE: The East Lawn (across the street from the Paepcke Memorial Building) WHO: Representatives from PhRMA will be available for interviews while onsite.
https://www.phrma.org

Combination of Vague Rules Defining a Patient and Lack of Enforcement Leads to Program Abuse

Chartpack  |  From Our Network

The lack of an appropriate patient definition means hospitals can profit from 340B discounts for patients whose prescriptions should not qualify for 340B.
http://chartpack.phrma.org/programs-chartpack/medicines-in-340b/combination-of-vague-rules-defining-a-patient-and-lack-of-enforcement-leads-to-program-abuse

PhRMA & LLS: More than 240 Medicines in Development for Blood Cancers

PhRMA  |  Blog Post

Additional Resources Download the 2015 Report: 240+ Medicines in Development for Blood Cancers 2014 Report: 771 Medicines in Development for Cancer From Hope to Cures: Cancer And the really encouraging news for patients?
http://catalyst.phrma.org/phrma-lls-more-than-240-medicines-in-development-for-blood-cancers

Current Hospital Eligibility Criteria Do Not Match Program Goals

Chartpack  |  From Our Network

In 2014, 45% of all Medicare acute care hospitals participated in 340B.
http://chartpack.phrma.org/programs-chartpack/medicines-in-340b/current-hospital-eligibility-criteria-do-not-match-program-goals

More Than 240 Innovative Medicines in Development For Leukemia, Lymphoma and Other Blood Cancers

PhRMA  |  Press Release

“The more than 240 medicines in development for leukemia, lymphoma and other forms of blood cancer reflect biopharmaceutical research companies’ commitment to build on progress to date and help bring new treatment options to patients.”
https://www.phrma.org/press-release/more-than-240-innovative-medicines-in-development-for-leukemia-lymphoma-and-other-blood-cancers

PhRMA Statement on 2013 Special 301 Report

PhRMA  |  Press Release

The Special 301 process garners high-level attention from our trading partners -- attention that is needed to redress intellectual property violations and market access concerns within individual markets and to send signals to other U.S. trading partners that protecting American intellectual property is important to the U.S. economy.
https://www.phrma.org/press-release/phrma-statement-on-2013-special-301-report

List of 2017 Immuno-Oncology Medicines in Development

PhRMA  |  Report

More than 240 immuno-oncology treatments in development are accelerating progress for patients with cancer.
https://www.phrma.org

More than 430 Medicines in Development to Treat Chronic Diseases Affecting Older Americans

PhRMA  |  Blog Post

America’s biopharmaceutical research companies are developing more than 430 medicines targeting 15 leading chronic conditions that impact seniors.
http://catalyst.phrma.org/more-than-430-medicines-in-development-to-treat-chronic-diseases-affecting-older-americans

More Than 400 Innovative Medicines in Development For Top Chronic Diseases Affecting Older Americans

PhRMA  |  Press Release

The more than 400 medicines in the pipeline for diseases prevalent among older Americans have tremendous potential to improve and extend the lives of seniors, and reduce costly emergency room visits, hospitalizations and surgical procedures.”
https://www.phrma.org/press-release/more-than-400-innovative-medicines-in-development-for-top-chronic-diseases-affecting-older-americans

More than 430 New Medicines in Development for Top Chronic Diseases Affecting Older Americans

PhRMA  |  Press Release

Washington, D.C. (June 16, 2014) — America’s biopharmaceutical research companies are developing 435 innovative new medicines to target 15 leading chronic conditions affecting the Medicare population, according to a new .phrma.org/sites/default/files/pdf/2014-m...
https://www.phrma.org/press-release/more-than-430-new-medicines-in-development-for-top-chronic-diseases-affecting-older-americans

Nearly 300 Medicines in Development to Treat Two Leading Causes of Death

PhRMA  |  Press Release

Washington, D.C. (February 1, 2011) — Drug discoveries played a major role in reducing American deaths from heart attacks and stroke by 28% between 1997 and 2007, yet cardiovascular disease still claims an American life every 39 seconds. Working to reduce the toll further,...
https://www.phrma.org/press-release/nearly-300-medicines-in-development-to-treat-two-leading-causes-of-death

Statement on Global IP Agenda: 2009 Special 301 Report

PhRMA  |  Press Release

“The ‘Special 301‘ process continues to be effective in gaining high-level attention from our trading partners – attention that is needed to redress intellectual property violations and market access concerns.
https://www.phrma.org/press-release/phrma-statement-on-global-intellectual-property-agenda-2009-special-301-report

You have reviewed the first 75 results out of 427. Each page contains 25 results. You're on page 3.

prev 1 2 3 4 5 6 next